Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

01885

Sigma-Aldrich

Docetaxel

purum, ≥97.0% (HPLC)

Synonym(s):

Docetaxel anhydrous

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C43H53NO14
CAS Number:
Molecular Weight:
807.88
MDL number:
UNSPSC Code:
51101929
PubChem Substance ID:
NACRES:
NA.25

grade

purum

Quality Level

assay

≥97.0% (HPLC)

form

powder or crystals

impurities

~6% water

mp

186-192 °C (dec.)

application(s)

metabolomics
vitamins, nutraceuticals, and natural products

SMILES string

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6

InChI

1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1

InChI key

ZDZOTLJHXYCWBA-VCVYQWHSSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Docetaxel is a cytotoxic, semisynthetic, second-generation taxane derived from the needles of the European yew tree , with a baccatin ring , and is an anthracycline antibiotic. It is related to paclitaxel but structurally it differs from paclitaxel on the 3′ position of the side chain and 10′ position of the baccatin ring.

Application

Docetaxel has been used:
  • to test its effect on lysosomal autophagic flux in gastric cancer cells
  • in combination with stearidonic acid (SDA) to increase its efficacy and enhancing cell death in human prostate cancer cells
  • as a microtubule-stabilizing agent in prostate and cervical cancer cells
  • in combination with a γ-secretase inhibitor (GSI) in prostate cancer stem-like cells (PCSCs) to test its effect on the notch signaling pathway

Biochem/physiol Actions

Docetaxel (DOC) is an anti-microtubule agent , a standard anti-cancer drug used in first-line chemotherapy treatment in many types of cancer including prostate and breast cancer. It elicits a stronger effect of inhibiting angiogenesis in both in vitro and in vivo by acting on vascular endothelial growth factor (VEGF) associated with tumor cells. Being involved in many key cellular processes such as cell cycle, angiogenesis, and gene expression; docetaxel interacts with many signaling pathways, such as the epidermal growth factor receptor (EGFR) pathway, Ras pathway, etc.
Docetaxel is a taxane anti-cancer agent related to paclitaxel. It binds to and stabilizes the β−tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest and apoptosis.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Eye Irrit. 2 - Lact. - Muta. 2 - Repr. 1B - Skin Irrit. 2 - STOT RE 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mahmoud Mansour et al.
Journal of Cancer, 9(23), 4536-4546 (2018-12-07)
Background: Docetaxel (DOC), or Taxotere, is an anthracycline antibiotic used to treat multiple types of cancer. It is a first-line chemotherapy treatment for patients with metastasized, hormone-resistant prostate cancer (PCa) or for patients with high-risk, localized PCa that could benefit
Alberto Montero et al.
The Lancet. Oncology, 6(4), 229-239 (2005-04-07)
Docetaxel is a semisynthetic taxane, a class of anticancer agents that bind to beta tubulin, thereby stabilising microtubules and inducing cell-cycle arrest and apoptosis. Docetaxel was first approved for the treatment of anthracycline-refractory metastatic breast cancer in the mid-1990s. Since
Hugo E R Ford et al.
The Lancet. Oncology, 15(1), 78-86 (2013-12-18)
Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for
Roy S Herbst et al.
Cancer treatment reviews, 29(5), 407-415 (2003-09-16)
Different tumors have different aberrations in signaling and growth stimulation pathways that drive cancer growth. An understanding of these processes is key to the development of new anticancer agents and to identifying optimal treatment strategies and patient populations suitable for
Giuseppe Di Lorenzo et al.
European urology, 54(5), 1089-1094 (2008-02-16)
Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice for

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service